Retatrutide Complete Guide: The Triple Agonist That Outperforms Every GLP-1 Drug

A new class of obesity treatment is emerging — and it's more powerful than anything that came before it. Retatrutide (LY3437943), developed by Eli Lilly, is a first-in-class triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 data shows average weight loss of up to 28.7% — numbers that would have seemed impossible just five years ago.

Here's everything you need to know about how it works, what the clinical trials show, and where it stands today.

What Is Retatrutide?

Retatrutide is an investigational once-weekly injectable peptide. Structurally, it is a single peptide molecule coupled to a fatty diacid moiety that extends its half-life to approximately six days, enabling convenient once-weekly subcutaneous dosing.

What sets retatrutide apart is its three-pronged mechanism. While semaglutide (Ozempic/Wegovy) targets only GLP-1 receptors, and tirzepatide (Mounjaro/Zepbound) hits GLP-1 and GIP receptors, retatrutide adds glucagon receptor agonism — a third pathway that significantly amplifies energy expenditure and fat metabolism.

Mechanism of Action: How Triple Agonism Works

GLP-1 Receptor Activation

Glucagon-like peptide-1 receptor agonism is the foundation of modern obesity pharmacology. Activating GLP-1R enhances glucose-stimulated insulin secretion, slows gastric emptying (promoting satiety), and reduces appetite at the hypothalamic level — the same pathway used by semaglutide and liraglutide.

GIP Receptor Activation

Glucose-dependent insulinotropic polypeptide (GIP) receptor activation facilitates insulin secretion in a glucose-dependent manner and plays a key role in lipid metabolism — reducing fat deposition and improving overall energy balance. Tirzepatide introduced this dual-agonism to great clinical effect; retatrutide carries it forward.

Glucagon Receptor Activation

This is the differentiating feature. Glucagon receptor (GCGR) agonism promotes thermogenesis, accelerates hepatic lipid oxidation, and increases energy expenditure. Glucagon alone raises blood sugar — but when balanced with GLP-1 and GIP agonism, the hyperglycemic effect is neutralized while the fat-burning benefits are preserved. The result is a compound that does not just suppress appetite; it actively drives the body to burn more fat.

Structural analysis published in Cell Discovery confirmed retatrutide's simultaneous binding to all three receptor types, with the fatty diacid moiety providing the extended pharmacokinetic profile needed for weekly dosing.

Clinical Trial Results

Phase 2 Trial (NEJM, 2023)

The pivotal Phase 2 obesity trial, published in the New England Journal of Medicine, enrolled adults with BMI ≥30 (or ≥27 with a weight-related comorbidity) and randomized them to retatrutide 1 mg, 4 mg, 8 mg, or 12 mg once weekly versus placebo for 48 weeks.

Weight loss at 24 weeks:

• 1 mg: −7.2%
• 4 mg: −12.9%
• 8 mg: −17.3%
• 12 mg: −17.5%
• Placebo: −1.6%

By 48 weeks, the 12 mg arm reached approximately 24% mean body weight reduction — a trajectory never seen with an injectable peptide at that stage. For context, semaglutide 2.4 mg achieves ~15% in the STEP trials; tirzepatide 15 mg achieves ~22% in the SURMOUNT trials.

Phase 3 — TRIUMPH-4 Trial (December 2025)

TRIUMPH-4 evaluated retatrutide in adults with obesity or overweight and knee osteoarthritis (without diabetes) over 68 weeks. Results announced in December 2025:

• 12 mg dose: average weight loss of 28.7% (~71.2 lbs / ~32.3 kg)
• 9 mg dose: average weight loss of 26.4%
• Placebo: −2.1%

Participants on 12 mg also saw a 75.8% reduction in WOMAC pain scores — a clinically meaningful result for patients where excess weight directly drives joint pain. Retatrutide additionally improved cardiovascular risk markers including non-HDL cholesterol and systolic blood pressure.

Phase 3 — TRANSCEND-T2D-1 Trial (March 2026)

In Lilly's type 2 diabetes Phase 3 trial, retatrutide met all primary and key secondary endpoints at 40 weeks:

• A1C reductions of up to −2.0%
• Body weight reduction of up to −16.8% (~36.6 lbs)

These results position retatrutide as a compelling option for T2D patients who need both glycemic control and substantial weight loss.

Retatrutide vs. Semaglutide vs. Tirzepatide

The benefit from adding glucagon receptor agonism is real and substantial — roughly 6–8 percentage points of additional weight loss versus tirzepatide. For a 250-pound patient, that translates to 15–20 additional pounds lost.

Dosing Protocol (Clinical Trial Data)

Based on Phase 3 trial protocols, retatrutide uses a step-wise dose escalation:

• Weeks 1–4: 2 mg once weekly (starting dose)
• Weeks 5–8: Escalate to 4 mg
• Weeks 9+: Continue escalation toward maintenance
• Maintenance: 4 mg, 9 mg, or 12 mg once weekly

Slow titration is critical. Starting at 2 mg significantly reduces nausea and vomiting compared to starting at 4 mg — a lesson learned in Phase 2 that directly shaped the Phase 3 design.

Note: Retatrutide is not FDA-approved. The above is from published clinical trial protocols only and does not constitute medical advice.

Safety Profile and Side Effects

Common Side Effects

• Gastrointestinal: Nausea, vomiting, diarrhea, constipation — dose-dependent, mostly mild-to-moderate, and typically resolving after initial weeks with slow titration.
• Heart rate: Modest dose-dependent increases, peaking at 24 weeks and declining thereafter — consistent with GLP-1 class agents.

New Safety Signal: Dysesthesia

TRIUMPH-4 identified a novel finding not seen with semaglutide or tirzepatide: dysesthesia (abnormal skin sensations — tingling, burning, numbness) occurred in 20.9% of participants on 12 mg versus 0.7% on placebo. This is believed to be related to glucagon receptor activation. It rarely led to discontinuation but is an important differentiator that clinicians will need to monitor.

Serious Adverse Events

In Phase 2, serious adverse event rates ranged from 0–6% across retatrutide groups versus 4% for placebo — consistent with obesity pharmacotherapy broadly.

The Full Phase 3 Program

Eli Lilly is running eight Phase 3 trials across multiple indications under the TRIUMPH, TRANSCEND, and SYNERGY programs:

• TRIUMPH: Obesity with comorbidities (knee osteoarthritis, sleep apnea, chronic low back pain, cardiovascular outcomes)
• TRANSCEND: Type 2 diabetes
• SYNERGY: Metabolic dysfunction-associated steatotic liver disease (MASLD)

Seven additional trials are expected to report results throughout 2026, completing the evidence base needed for NDA submission.

FDA Approval Timeline

As of April 2026, retatrutide is not FDA-approved and not commercially available.

• Q4 2026 / Q1 2027: Expected NDA submission to the FDA
• Late 2027: Expected FDA approval (pending ~10-month standard review)
• Q1–Q2 2028: Projected commercial launch

Compounding pharmacies have begun marketing peptides labeled as "retatrutide," but these are unregulated research chemicals — not pharmaceutical-grade LY3437943. The FDA has not approved retatrutide in any form. Patients seeking access should look for open clinical trials at ClinicalTrials.gov (search NCT05931367 and related studies).

The Bottom Line

Retatrutide represents the most clinically significant advance in obesity pharmacotherapy since tirzepatide — and potentially the most potent injectable weight loss drug ever to enter Phase 3. Adding glucagon receptor agonism to GLP-1/GIP dual-agonism unlocks thermogenic and hepatic benefits that push efficacy into entirely new territory.

The 28.7% average weight loss in TRIUMPH-4 builds on consistent Phase 2 data and is corroborated across multiple trial designs. The novel dysesthesia signal warrants monitoring, but it has not derailed the program.

If the remaining Phase 3 trials hold and the NDA proceeds on schedule, retatrutide could reach patients in 2027–2028 — and when it does, it will reset expectations for what obesity treatment can achieve.